![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sequence Analysis of Baseline and On-treatment Samples from HBV-infected Chronic Hepatitis B Patients Treated for 28 Days with JNJ-56136379 Monotherapy
|
|
|
Reported By Jules Levin
EASL The International Liver Congress, Vienna, Austria, April 10-14, 2019
Thierry Verbinnen1, Moana Hodari1, Willem Talloen1, Jan Martin Berke1, David Blue2, Jeysen Yogaratnam2, Umesh Shukla3, Sandra De Meyer1, Oliver Lenz1
1Janssen Research & Development, Beerse, Belgium; 2Janssen Biopharma Inc., South San Francisco, CA, USA; 3Janssen Pharmaceuticals Research & Development, Titusville, USA
![0429191](../images/042919/042919-3/0429191.gif)
![0429192](../images/042919/042919-3/0429192.gif)
![0429193](../images/042919/042919-3/0429193.gif)
![0429194](../images/042919/042919-3/0429194.gif)
![0429195](../images/042919/042919-3/0429195.gif)
![0429196](../images/042919/042919-3/0429196.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|